Ftse Mib
33.629,21
-0,32%
DAX
18.001,60
0,54%
S&P 500
5.127,79
1,26%
NASDAQ
16.156,33
1,99%
Bitcoin
63.465,52
0,92%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Connect Biopharma Holdings Inc (CNTB) Connect Biopharma Holdings Inc (CNTB) Notizie

CNTB

Connect Biopharma (CNTB)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CNTB
DataOraFonteTitoloSimboloCompagnia
28/02/202403:00Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:CNTBConnect Biopharma Holdings Inc
13/02/202422:30Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:CNTBConnect Biopharma Holdings Inc
13/02/202422:27Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:CNTBConnect Biopharma Holdings Inc
12/02/202422:50Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CNTBConnect Biopharma Holdings Inc
23/06/202322:32Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:CNTBConnect Biopharma Holdings Inc
11/04/202322:59Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:CNTBConnect Biopharma Holdings Inc
11/04/202322:05GlobeNewswire Inc.Connect Biopharma Reports Full Year 2022 Financial Results and Provides Business UpdateNASDAQ:CNTBConnect Biopharma Holdings Inc
18/03/202319:40Business WireConnect Biopharma CBP-201 Atopic Dermatitis China Pivotal Study Showed Rapid Relief of Patient SymptomsNASDAQ:CNTBConnect Biopharma Holdings Inc
17/03/202321:05Business WireConnect Biopharma CBP-201 Atopic Dermatitis Global Phase 2b Data Showed Rapid and Sustained Improvement Across all Body RegionsNASDAQ:CNTBConnect Biopharma Holdings Inc
06/03/202314:15Business WireConnect Biopharma CBP-201 Atopic Dermatitis Abstracts from Two Trials Accepted for Presentation at the American Academy of Dermatology (AAD) Annual MeetingNASDAQ:CNTBConnect Biopharma Holdings Inc
14/02/202312:33Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:CNTBConnect Biopharma Holdings Inc
06/02/202314:30GlobeNewswire Inc.Connect Biopharma to Present at SVB Securities Global Biopharma Conference and Participate in BioCom CaliforniaNASDAQ:CNTBConnect Biopharma Holdings Inc
03/01/202322:32Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:CNTBConnect Biopharma Holdings Inc
30/12/202213:30GlobeNewswire Inc.Connect Biopharma Provides Business and Clinical Development Program UpdateNASDAQ:CNTBConnect Biopharma Holdings Inc
19/12/202214:00GlobeNewswire Inc.Connect Biopharma to Present at the San Francisco Biotech Showcase in JanuaryNASDAQ:CNTBConnect Biopharma Holdings Inc
02/12/202223:00GlobeNewswire Inc.Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price RequirementNASDAQ:CNTBConnect Biopharma Holdings Inc
27/10/202222:05GlobeNewswire Inc.Connect Biopharma To Present at Upcoming Investor and Scientific ConferencesNASDAQ:CNTBConnect Biopharma Holdings Inc
05/10/202214:45TipRanksConnect Biopharma Holdings (CNTB) Receives a Buy from JefferiesNASDAQ:CNTBConnect Biopharma Holdings Inc
04/10/202214:56GlobeNewswire Inc.CORRECTING and REPLACING -- Connect Biopharma Reports CBP-201 Achieved All Primary and Key Secondary Endpoints in Pivotal Atopic Dermatitis (AD) Trial in ChinaNASDAQ:CNTBConnect Biopharma Holdings Inc
04/10/202213:00GlobeNewswire Inc.Connect Biopharma Reports CBP-201 Achieved All Primary and Key Secondary Endpoints in Pivotal Atopic Dermatitis (AD) Trial in ChinaNASDAQ:CNTBConnect Biopharma Holdings Inc
03/10/202222:10GlobeNewswire Inc.Connect Biopharma to Host a Conference Call Tuesday, October 4 to Discuss Topline Results for the Pivotal Trial in China of Lead Candidate, CBP-201, in Patients with Moderate-to-Severe Atopic DermatitisNASDAQ:CNTBConnect Biopharma Holdings Inc
13/09/202222:05GlobeNewswire Inc.Connect Biopharma Reports First Half 2022 Financial Results and Provides Business UpdateNASDAQ:CNTBConnect Biopharma Holdings Inc
01/09/202214:00GlobeNewswire Inc.Connect Biopharma to Report First Half 2022 Financial Results on September 13NASDAQ:CNTBConnect Biopharma Holdings Inc
30/08/202214:00GlobeNewswire Inc.Connect BioPharma Successfully Completes CBP-174 Phase 1 Single Ascending Dose StudyNASDAQ:CNTBConnect Biopharma Holdings Inc
14/07/202208:18TipRanksSVB Securities Thinks Connect Biopharma Holdings’ Stock is Going to RecoverNASDAQ:CNTBConnect Biopharma Holdings Inc
11/07/202222:05GlobeNewswire Inc.Connect Moves Forward CBP-201 Top-Line Results Timeline for Pivotal China Atopic Dermatitis Trial to Second Half 2022NASDAQ:CNTBConnect Biopharma Holdings Inc
07/07/202212:03Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:CNTBConnect Biopharma Holdings Inc
01/07/202223:13Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:CNTBConnect Biopharma Holdings Inc
02/06/202222:05GlobeNewswire Inc.Connect Biopharma to Participate at the Jefferies Healthcare ConferenceNASDAQ:CNTBConnect Biopharma Holdings Inc
23/05/202212:02Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-3/a)NASDAQ:CNTBConnect Biopharma Holdings Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CNTB

La tua Cronologia

BIT
ISP
Intesa Sanpaolo
BIT
UCG
Unicredit
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
STLAM
Stellantis NV
BIT
ENEL
Enel
BIT
STMMI
ST Microelectronics
BIT
BPE
Bper Banca
BIT
BAMI
Banco BPM
BIT
ENI
Eni
BIT
RACE
Ferrari NV
BIT
TIT
Telecom Italia
BIT
SPM
Saipem
BIT
SRG
Snam
BIT
TEN
Tenaris
BIT
TRN
Terna Trasmissione Elett...
BIT
IVG
Iveco Group NV
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network